NCT06031558View on ClinicalTrials.gov

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

PHASE3RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

September 20, 2024

Study Completion Date

June 20, 2026

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

SY-5007

a RET selective Inhibitor

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Shouyao Holdings (Beijing) Co. LTD

OTHER